| Business Summary | | Curon
Medical
Inc.
develops,
manufactures
and
markets
products
for
the
treatment
of
gastrointestinal
disorders.
Its
products
consist
of
radio
frequency
generators
and
single-use
disposable
devices.
The
Company's
first
product,
the
Stretta
System,
is
indicated
for
gastroesophageal
reflux
disease
(GERD).
Unlike
medication,
which
temporarily
suppresses
GERD
symptoms,
the
Stretta
System
is
designed
to
apply
radio
frequency
energy
to
treat
the
causes
of
GERD.
The
Company's
second
product,
the
Secca
System,
is
currently
under
development
for
the
treatment
of
fecal
incontinence.
Curon
has
developed
a
suite
of
products
incorporating
design
features
for
use
in
the
Stretta
and
Secca
procedures.
These
products
consist
of
a
disposable
catheter
and
a
disposable
hand
piece
for
delivery
of
controlled
radio
frequency
energy
to
tissue
and
a
radio
frequency
generator,
known
as
the
Curon
Control
Module.
All
of
the
Company's
products
utilize
proprietary
software
to
interface
with
its
Curon
Control
Module. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Curon
Medical,
Inc.
develops,
manufactures
and
markets
proprietary
products
for
the
treatment
of
gastrointestinal
disorders.
For
the
six
months
ended
6/30/01,
revenues
totalled
$1.8
million,
up
from
$170
thousand.
Net
loss
decreased
10%
to
$7.3
million.
Revenues
reflect
the
begining
of
commercial
shipments
of
the
Stretta
System
in
June
2000.
Lower
net
loss
reflects
decreased
research
and
development
expenses
and
higher
interest
income. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Michael Berman, 43 Chairman | -- | -- | John Morgan, 41 Pres,
CEO, Director | $250K | $130K | Alistair McLaren, 60 CFO,
VP of Fin. and Admin. | 183K | 35K | Jim Goode VP
of Sales | -- | -- | Carol Chludzinski, 46 VP
of Marketing | 165K | 24K | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|